Hormone replacement therapy regimens and breast cancer risk

Obstetrics and Gynecology

Volumn 100, Issue 6, 2002, Pages 1148-1158

  Weiss, Linda K ^{a,b,c,d,e,f,g,h,i,j}   Burkman, Ronald T ^{a,b,c,d,e,f,g,h,i,j}   Cushing Haugen, Kara L ^{a,b,c,d,e,f,g,h,i,j}   Voigt, Lynda F ^{a,b,c,d,e,f,g,h,i,j}   Simon, Michael S ^{a,b,c,d,e,f,g,h,i,j}   Daling, Janet R ^{a,b,c,d,e,f,g,h,i,j}   Norman, Sandra A ^{a,b,c,d,e,f,g,h,i,j}   Bernstein, Leslie ^{a,b,c,d,e,f,g,h,i,j}   Ursin, Giske ^{a,b,c,d,e,f,g,h,i,j}   Marchbanks, Polly A ^{a,b,c,d,e,f,g,h,i,j}   Strom, Brian L ^{a,b,c,d,e,f,g,h,i,j}   Berlin, Jesse A ^{a,b,c,d,e,f,g,h,i,j}   Weber, Anita L ^{a,b,c,d,e,f,g,h,i,j}   Doody, David R ^{a,b,c,d,e,f,g,h,i,j}   Wingo, Phyllis A ^{a,b,c,d,e,f,g,h,i,j}   McDonald, Jill A ^{a,b,c,d,e,f,g,h,i,j}   Malone, Kathleen E ^{a,b,c,d,e,f,g,h,i,j}   Folger, Suzanne G ^{a,b,c,d,e,f,g,h,i,j}   Spirtas, Robert ^{a,b,c,d,e,f,g,h,i,j}  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^h Section on Membrane Biology Program of Physical Biology Institute of Child Health and Human Development   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j BAYSTATE MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAMMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES;

ADULT; AGE DISTRIBUTION; AGE OF ONSET; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; PREVALENCE; PROBABILITY; PROGNOSIS; REFERENCE VALUES; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 0036899920     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(02)02502-4     Document Type: Article

References (42)

1. Wysowski D.K., Golden L., Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol. 85:1995;6-10.
2. Harris R.B., Saws A., Reddy V.M., King A., Haskell W.L. Are women using menopausal estrogens? A community survey. Am J Public Health. 80:1990;1266-1268.
3. Stafford R.S., Saglam D., Causino N., Blumenthal D. Low rates of hormone replacement in visits to United States primary care physicians. Am J Obstet Gynecol. 177:1997;381-387.
4. Finley C., Gregg E.W., Solomon L.J., Gay E. Disparities in hormone replacement therapy use by socioeconomic status in a primary care population. J Community Health. 26:2001;39-50.
5. Brown A.F., Perez-Stable E.J., Whittaker E.E., Posner S., Alexander M., Gathe J., et al. Ethnic differences in hormone replacement prescribing patterns. J Gen Intern Med. 14:1999;663-669.
6. Latner A.W. Top 200 drugs of 2000 Drugs of the new millennium . Pharmacy Times. 67:2001;14-29.
7. Ross R.K., Paganini-Hill A., Gerkins V.R., Mack T.M., Pfeffer R., Arthur M., et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA. 243:1980;1635-1639.
8. Brinton L.A., Hoover R.M., Szklo M., Fraumeni J.F. Menopausal estrogen use and risk of breast cancer. Cancer. 47:1981;2517-2522.
9. Wingo P.A., Layde P.M., Lee N.C., Rubin G., Ory H.W. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA. 257:1987;209-215.
10. Bergkvist L., Adami H.O., Persson I., Hoover R., Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med. 321:1989;293-297.
11. Kaufman D.W., Palmer J.W., de Mouzon J., Rosenberg L., Stolley P.D., Warshauer M.E., et al. Estrogen replacement therapy and the risk of breast cancer Results from the case-control surveillance study . Am J Epidemiol. 134:1991;1375-1385.
12. Hulka B.S., Chambliss L.E., Deubner D.C., Wilkinson W.E. Breast cancer and estrogen replacement therapy. Am J Obstet Gynecol. 143:1992;638-644.
13. Schairer C., Byrne C., Keyl P.M., Brinton L.A., Sturgeon S.R., Hoover R.N. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control. 5:1994;491-500.
14. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332:1995;1589-1593.
15. LaVecchia C., Negri E., Franceschi S., Favero A., Nanni O., Filiberti R., et al. Hormone replacement treatment and breast cancer risk A cooperative Italian study . Br J Cancer. 72:1995;244-248.
16. Newcomb P.A., Longnecker M.P., Storer B.E., Mittendorf R., Baron J., Clapp R.W., et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol. 142:1995;788-795.
17. Stanford J.L., Weiss N.S., Voight L.F., Daling J.R., Habel L.A., Rossing M.A. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 274:1995;137-142.
18. Persson I., Weiderpass E., Bergkvist L., Bergstrom R., Schairer C. Risk of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 10:1999;253-260.
19. Magnusson C., Baron J.A., Correia N., Bergstrom R., Adami H.O., Persson I. Breast cancer risk following long-term oestrogen and oestrogen-progestin-replacement therapy. Int J Cancer. 81:1999;339-344.
20. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283:2000;485-491.
21. Ross R.K., Paganini-Hill A., Wan P., Pike M.C. Effect of hormone replacement therapy on breast cancer risk Estrogen versus estrogen plus progestin . J Natl Cancer Inst. 92:2000;328-332.
22. Chen C.L., Weiss N.S., Newcomb P., Barlow W., White E. Hormone replacement therapy in relation to breast cancer. JAMA. 287:2002;734-741.
23. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 288:2002;321-333.
24. Marchbanks P.A., McDonald J.A., Wilson H.G., Burnett N.M., Daling J.R., Bernstein L., et al. The NICHD Women's Contraceptive and Reproductive Experiences Study Methods and operational results . Ann Epidemiol. 12:2002;213-221.
25. Rizzo R., DiGaetano R., Cadell D. The Women's CARE Study The results of an experiment in new sampling designs for random digit dialing surveys . Proceedings of the American Statistical Association. Vol II. Alexandria, Virginia: American Statistical Association, 1995:644-9 Am J Epidemiol. 120:1984;825-833.
26. Hartge B.L., Brinton L.A., Rosenthal J.F., Cahill J.I., Hoover R.N., Waksberg J. Random digit dialing in selecting a population-based control group. Am J Epidemiol. 120:1984;825-833.
27. Aday L. Designing and conducting health surveys. 2nd ed: 1996;Jossey-Bass Publishers, San Francisco.
28. Breslow N.E., Day N.E. Statistical methods in cancer research. volume II:1987;97 Oxford University Press, Oxford, United Kingdom.
29. Breslow N.E., Day N.E. Statistical methods in cancer research, volume I. 1980;Oxford University Press, Oxford, United Kingdom.
30. Hosmer D.W., Lemeshow S. Applied logistic regression. 1989;John Wiley & Sons, New York.
31. SEER extent of disease 1988, codes and coding instructions. 3rd ed: 1998;National Institutes of Health, Bethesda, Maryland.
32. Pike M.C., Ross R.K., Spicer D.V. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol. 147:1998;718-721.
33. Rockhill B., Colditz G.A., Rosen B. Bias in breast cancer analyses due to error in age at menopause. Am J Epidemiol. 151:2000;404-408.
34. Weiss N.S., Rossing M.A. Healthy screenee bias in epidemiologic studies of cancer incidence. Epidemiology. 7:1996;319-322.
35. Breast cancer and hormone replacement therapy Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer . Lancet. 350:1997;1047-1059.
36. Raafat A.M., Hofseth L.J., Haslam S.Z. Proliferative effects of combination estrogen and progesterone replacement therapy on the normal postmenopausal mammary gland in a murine model. Am J Obstet Gynecol. 184:2001;340-349.
37. Raafat A.M., Songjiang L., Bennett J.M., Hofseth L.J., Haslam S.Z. Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model. J Cell Physiol. 187:2001;81-89.
38. Hofseth L.J., Raafat A.M., Osuch J.R., Pathak D.R., Slomski C.A., Haslam S.Z. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal post-menopausal breast. J Clin Endocrinol Metab. 84:1999;4559-4565.
39. Greendale G.A., Reboussin B.A., Sie A., Singh H.R., Olson L.K., Gatewood O., et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med. 130:1999;262-269.
40. Lundstrom E., Wilczek B., von Palffy Z., Soderqvist G., vonSchoultz B. Mammographic breast density during hormone replacement therapy Differences according to treatment . Am J Obstet Gynecol. 181:1999;348-352.
41. Santen R.J., Pinkerton J., McCartney C., Petroni G. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab. 86:2001;16-23.
42. Foidart J.M., Colin C., Denoo X., Desreux J., Beliard A., Fournier S., et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril. 69:1998;963-969.